ICBI provides access to a variety of funding sources for translational research, and technology development and commercialization. Indiana CTSI offers milestone-based grant support for assay and model development through the CORE grant, screening and identification of potential drug molecules through the Molecular Therapeutics grant, development of proof of concept for drug, device, cell or gene therapy and diagnostics through the CRT grant and further product development through the Technology Enhancement Award (TEA ). ICBI provides support and guidance for SBIR/STTR applications and connections to angel and venture capital investors.
The Indiana Clinical and Translational Sciences Institute (CTSI) and Indiana University offer a variety of funding opportunities that are open to IUSM researchers. These include funding for basic research and clinical trials as well as specialized opportunities for equipment.
Technology Enhancement Award (TEA)
In partnership with Indiana CTSI, IU School of Medicine, IU Health and Industry Collaboration Portal (ICP), the Indiana Center for Biomedical Innovation (ICBI) will support early stage technologies by providing funds through Technology Enhancement Awards (TEA) grant program. The awardees will receive funding up to $50,000 and mentorship support through the ICBI advisory council and SPARK-Stanford partenship. Submission deadline September 29, 2017 – Online application: Technology Enhancement Award (TEA)
Medical Device Development Award (MDDA)
In partnership with Indiana CTSI, Indiana Center for Biomedical Innovation (ICBI) will support the development of nascent medical device technologies invented by Indiana University clinicians by providing funds through Medical Device Development Award (MDDA) grant program. The awardees will receive funding up to $50,000 and mentorship support through the ICBI Advisory Council and SPARK-Stanford partnership. Submission Deadline July 31, 2017– Online application: ICBI Medical Device Development Award (MDDA)
Indiana Drug Discovery Alliance (IDDA)
The Indiana Drug Discovery Alliance (IDDA) aims to promote and support promising early-stage drug discovery research in Indiana. IDDA facilitates collaborative translational research and partnerships through identification of complementary expertise and support for team building across diverse disciplines. Small grants are available to support new collaborations and/or the use of core facilities that enable the translation of fundamental discoveries related to drug discovery. Submission Deadline June 30, 2017– Online application: IndianaCTSI_IDDA grant
Strategic Pharma-Academic Research Consortium (SPARC) Awards Program
The Midwest Strategic Pharma-Academic Research Consortium (SPARC) is a group of universities and pharmaceutical companies dedicated to addressing research challenges facing the pharmaceutical industry. The research is in the non-competitive space of mutual interest that addresses scientific and technological research challenges confronting the pharmaceutical industry. SPARC’s founding members are Indiana University, Northwestern University, Ohio State University, Washington University in St. Louis, Eli Lilly and Company, and Takeda Pharmaceuticals
GSK Discovery Fast Track Challenge
The Discovery Fast Track Challenge is a challenge that recognizes and rewards innovative concepts, discoveries, and research by investigators at U.S. and Canadian research institutions, colleges, and universities. Winning investigators will collaborate with a team of GSK scientists to put their innovative research concept on an accelerated drug discovery path.
Johnson & Johnson Innovation Centers
The Johnson & Johnson Innovation Centers catalyze, support, and invest in highly differentiated early-stage innovations. The Centers bring together resources from across the company to meet the needs of entrepreneurs and scientists developing the important medical device and diagnostic technologies, consumer health care products, and pharmaceuticals.
Lilly Open Innovation Drug Discovery
The Lilly Open Innovation Drug Discovery platform provides access to internal screening assays for external investigators as an in-kind contribution to their research.
Pfizer Centers for Therapeutic Innovation
The Pfizer Centers for Therapeutic Innovation partner with academic medical centers and disease foundations to translate research ideas into clinical applications, offering funding and resources to principal investigators and postdocs at academic medical centers to continue development and research on a promising therapeutic or hypothesis. Throughout the year, CTI issues call for proposals to academic medical centers.